The ability to trigger RNA interference in mammalian cells provides unprecedented opportunities for probing the functions of genes. Many products and resources are there to help. Laura Bonetta ...

The final word in target validation is to reintroduce an RNAi-resistant version of the target gene product into depleted cells and show recovery of function. This can be challenging for large sets ...

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...

RNAi modulates gene expression ... Moreover, Amvuttra’s regulatory approval for ATTR-CM could give ALNY a product that has a decent shot at becoming the standard-of-care [SoC] for first-line ...

City Therapeutics™ aims to harness next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to build a robust and sustainable product ...

Codexis Demonstrates First-ever Enzymatic Synthesis of Approved siRNA Therapeutic ...